Dr. Reddy’s signs multimillion dollar deal with Hatchtech

Hyderabad, Sep 14 (IANS) Pharma major Dr. Reddy’s Laboratories on Monday announced the signing of a multi-million dollar commercialisation deal with Hatchtech, an Australian pharmaceutical company developing an anti-headlice Xeglyze lotion.

The exclusive rights for this product are applicable for the US, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela.

Hatchtech also announced that it will be filing its New Drug Application for Xeglyze with the US Food and Drug Administration (FDA).

If approved, the product will be marketed in the US by Promius Pharma, a wholly-owned specialty company of Dr. Reddy’s.

As part of the agreement, Dr. Reddy’s will pay Hatchtech an upfront amount of $10 million, up to $50 million based on pre commercialisation milestones and an undisclosed amount based on post commercialization milestones, linked to achievement of annual net sales targets, said a statement by Hyderabad-based firm.

Hatchtech last year announced positive results from its two pivotal Phase 3 clinical studies evaluating Xeglyze lotion as a potential treatment for head lice infestation.

The active drug substance was developed in collaboration with Dr. Reddy’s Custom Pharmaceutical Services (CPS) business unit.

Leave a Reply

Please enter your comment!

The opinions, views, and thoughts expressed by the readers and those providing comments are theirs alone and do not reflect the opinions of www.mangalorean.com or any employee thereof. www.mangalorean.com is not responsible for the accuracy of any of the information supplied by the readers. Responsibility for the content of comments belongs to the commenter alone.  

We request the readers to refrain from posting defamatory, inflammatory comments and not indulge in personal attacks. However, it is obligatory on the part of www.mangalorean.com to provide the IP address and other details of senders of such comments to the concerned authorities upon their request.

Hence we request all our readers to help us to delete comments that do not follow these guidelines by informing us at  info@mangalorean.com. Lets work together to keep the comments clean and worthful, thereby make a difference in the community.

Please enter your name here